Modified RNA VEGF-A Citrate Saline Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for controlling and augmenting VEGF-A pathways for therapeutic effects are limited by systemic side effects, immune activation, and dose-dependent toxicities, particularly with lipid-based nucleic acid formulations, which restrict their applicability in treating vascular and cardiovascular diseases.
Innovation Solution
Modified RNA molecules encoding VEGF-A polypeptides formulated in citrate saline buffer, free of divalent cations, are used to achieve targeted protein expression with reduced toxicity, allowing for effective treatment of diseases such as heart failure and vascular injuries.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If lipid-based nucleic acid formulations are used to deliver RNA therapeutics, then RNA encapsulation and stability are improved, but dose-dependent toxicities occur including tissue injury, immune activation, and cell lysis
Solution Approach 1:
The patent removes harmful cationic lipids from the formulation while retaining the beneficial RNA delivery function through alternative buffering systems (citrate saline buffer), thereby eliminating dose-dependent toxicities including cell lysis and immune activation
Solution Approach 2:
The patent changes the formulation parameters by using citrate saline buffer instead of cationic lipids, fundamentally altering the chemical composition to achieve both RNA stability and reduced toxicity profile
2Reliability
If VEGF-A protein is administered systemically to achieve therapeutic effects, then vascular function is improved, but significant hypotension and rapid degradation occur
Solution Approach 1:
The patent uses modified RNA to encode VEGF-A protein, allowing the body's cellular machinery to produce the therapeutic protein locally and sustainedly, thereby extending the duration of action and avoiding rapid degradation of systemically administered protein
Solution Approach 2:
The patent introduces modified RNA as an intermediary that carries the genetic information for VEGF-A production, enabling sustained endogenous protein synthesis rather than relying on direct protein administration that undergoes rapid degradation
3Productivity
If viral vectors are used to deliver VEGF-A DNA plasmids for in vivo expression, then protein expression is achieved, but immune system activation and limited temporal control occur
Solution Approach 1:
The patent removes viral vectors from the delivery system, using non-viral modified RNA formulations that achieve VEGF-A protein expression without triggering immune system activation
Solution Approach 2:
The patent uses transient modified RNA delivery that provides sufficient protein expression for therapeutic effect without the persistent immune activation risks associated with viral vectors, allowing the system to be cleared naturally after delivering its function
Data Source
AI summary
The disclosure relates to modified RNA molecules encoding VEGF-A polypeptides and formulations comprising the modified RNA. Aspects of the disclosure further relate to preparations and uses of formulations comprising the modified RNA in treating subjects suffering from diseases responsive to VEGF-A therapy.